Clinical trials: Genitourinary Syndrome of Menopause (GSM)
Women With Breast Cancer
Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer
The goal of this interventional study is to evaluate the effect of Intravaginal Prasterone for the treatment of moderate to severe symptoms of genitourinary syndrome (GSM) due to natural, surgical or treatment-induced menopause…
- Trial name
- PROPOSE (NCT06611514)
- Testing
- Prasterone (DHEA)
- Where
- Italy
- Volunteers
- 95 people
- Sponsor
- European Institute of Oncology
Genitourinary Syndrome of Menopause
Impact of Oral Supplementation With Bioactive Collagen Peptides and Other Functional Ingredients
Genitourinary Syndrome of Menopause (GSM), characterized by vaginal dryness, pain, urinary incontinence, and other symptoms, can be mitigated through both hormonal and non-hormonal treatments.
- Trial name
- Maicol (NCT07151482)
- Testing
- Collagendep
- Volunteers
- 43 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Vaginal Atrophy Patients With GSM
The Effect Of Fractional CO2 Laser Therapy On Cancer Survivors With Genitourinary Syndrome Of Menopause (GSM)
Improvement in cancer therapies has led to an increase in the number of women surviving chemotherapy (and other treatments) and overcoming cancer.
- Trial name
- NCT06318052
- Testing
- The FemTouch delivery system, Gynomunal gel treatment
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Lumenis Be Ltd.
Genitourinary Syndrome of Menopause
Laser Therapy for Treatment of Genitourinary Syndrome of Menopause (GSM) in Postmenopausal Women
This is a prospective, multi-centre, double blinded, randomized controlled trial, which will be conducted under a common protocol.
- Trial name
- LASER_2022 (NCT05305209)
- Testing
- Intervention group, Control Group
- Where
- Spain
- Volunteers
- 189 people
- Sponsor
- University of Malaga
Vaginal Atrophy, Genitourinary Disease
Effect of Hybrid Laser 10600+1540 nm on GSM
The primary objective of the study is to clinically confirm, by comparison with a control group, the performance of the 10600 +1540 nm laser in the improvement of atrophic vaginal epithelium at 3 months after the last laser…
- Trial name
- NCT03956563
- Testing
- Youlaser MT Group 2, Youlaser MT Group 1
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Quanta System, S.p.A.
Genitourinary Syndrome of Menopause (GSM)
Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study
This study aims to evaluate whether the administration of vaginal estrogen along with Via, a hyaluronic acid-based vaginal moisturizer, offers superior relief from symptoms of genitourinary syndrome of menopause (GSM) in the…
- Trial name
- NCT07038070
- Testing
- Vaginal estrogen tablet, Via Solv Wellness (Hyaluronic Acid Therapy)
- Where
- United States
- Sponsor
- NYU Langone Health
Vaginal Atrophy, Atrophic Vaginitis
ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy
Vaginal atrophy patients receiving vaginal laser therapy will be treated with daily 7-0940® following a laser session to evaluate the safety and efficacy of the product as an adjunct treatment.
- Conditions
- Vaginal Atrophy, Atrophic Vaginitis, Genitourinary Syndrome of Menopause (GSM)
- Trial name
- ASSIST-VLA (NCT07346287)
- Testing
- 7-940
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stratpharma AG
Genitourinary Syndrome of Menopause (GSM)
Vaginal Platelet-Rich Plasma and Vaginal Histology in Genitourinary Syndrome of Menopause
This study evaluates whether subepithelial injection of autologous platelet-rich plasma (PRP) into the vaginal wall produces histological changes consistent with tissue regeneration in postmenopausal women with genitourinary…
- Trial name
- NCT07905820
- Testing
- Autologous Platelet-Rich Plasma (PRP), 0.9% sodium chloride (normal saline)
- Where
- Greece
- Volunteers
- 20 people
- Sponsor
- National and Kapodistrian University of Athens
Genitourinary Syndrome of Menopause (GSM)
CO₂ Laser With or Without Platelet-Rich Plasma for Genitourinary Syndrome of Menopause
This study evaluated whether adding platelet-rich plasma (PRP) to fractional CO₂ laser treatment provides additional benefit for postmenopausal women with genitourinary syndrome of menopause (GSM).
- Trial name
- NCT07863739
- Testing
- Fractional CO₂ Laser, Autologous Platelet-Rich Plasma (PRP)
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- National and Kapodistrian University of Athens
Genitourinary Syndrome of Menopause (GSM), Breast Cancer Female
Genitourinary Syndrome of Menopause in Breast Cancer
This randomized, single-blind clinical trial will compare the effectiveness of multimodal pelvic floor physiotherapy (PPT) and fractional CO2 vaginal laser therapy in reducing genitourinary syndrome of menopause (GSM) symptoms…
- Trial name
- PILME (NCT06721936)
- Testing
- Multimodal pelviperineal physioterapy group, Laser CO2 Therapy group
- Where
- Spain
- Volunteers
- 182 people
- Sponsor
- University of Alcala
Vaginal Atrophy, Dyspareunia
Elastographic Improvement of Vaginal Atrophy Treated by Erbium Yag Laser
This study is a randomized controlled sham applied study. Its aim is to evaluate the efficacy of Er:YAG laser for the treatment of atrophic vaginitis in postmenopausal women.
- Conditions
- Vaginal Atrophy, Dyspareunia, Laser, Genitourinary Syndrome of Menopause (GSM)
- Trial name
- NCT06000202
- Testing
- Fotona Dynamis Er:YAG Laser System
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Istanbul University - Cerrahpasa
Genitourinary Syndrome of Menopause (GSM)
A Randomized, Single Center Pilot Study Comparing Hyaluronic Acid to Vaginal Estrogen for Treatment of Genitourinary Syndrome of Menopause
Non-hormonal alternatives for the treatment of genitourinary syndrome of menopause (GSM) are needed. In this proposed trial, patients who are diagnosed with GSM will be randomized to receive either a hyaluronic acid (HLA) vaginal…
- Trial name
- NCT04544475
- Testing
- Revaree, Estrace
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Vulvar Atrophy, Vulvovaginal Signs and Symptoms
Changes in the Impact of Genitourinary Syndrome of Menopause With a Novel Nonhormonal Vulvovaginal Gel Assessed by PROMs.
The goal of this clinical trial is to improve the management of Genitourinary syndrome of menopause (GSM) to preliminary assess safety and effectivity of a novel hormone-free mucosa composition (XCMIM20m) applied topically to the…
- Conditions
- Vulvar Atrophy, Vulvovaginal Signs and Symptoms, Genitourinary Syndrome of Menopause, Quality of Life
- Trial name
- STOPGSMP (NCT06962345)
- Testing
- Hormone-free vulvovaginal gel with the tested composition XCMIM20m
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Mucosa Innovations, S.L.
Genitourinary Abnormality, Breast Cancer Female
GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors
The impact of treatment for GSM on the quality of life will be examined for postmenopausal women (defined as last menstrual period > 1 year ago or 6 months ago with FSH >40) who have been diagnosed with breast cancer.
- Conditions
- Genitourinary Abnormality, Breast Cancer Female, Vaginal Abnormality, Urinary Tract Infections
- Trial name
- GSM (NCT03185169)
- Testing
- Replens and coconut oil
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Alta Bates Summit Medical Center
Genitourinary Syndrome of Menopause (GSM)
Bipolar Radiofrequency for Genitourinary Syndrome of Menopause
This randomized, sham-controlled clinical trial aims to evaluate the efficacy and safety of bipolar radiofrequency in the treatment of genitourinary syndrome of menopause (GSM) in postmenopausal women.
- Trial name
- BRF-GSM (NCT07419035)
- Testing
- Active bipolar radiofrequency therapy
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- University of Castilla-La Mancha
Genitourinary Syndrome of Menopause
The Outcome of Chinese Women With Genitourinary Syndrome of Menopause Treated With Vaginal Dehydroepiandrosterone
Genitourinary syndrome of menopause (GSM) is a common condition with prevalence was up to 80%. Symptoms associated with GSM include vaginal or vulvar dryness, itchiness, dyspareunia, increased urinary frequency or urgency and…
- Trial name
- NCT05434351
- Testing
- vaginal dehydroepiandrosterone
- Where
- Hong Kong
- Volunteers
- 4 people
- Sponsor
- Chinese University of Hong Kong